Windtree Announces Expansion Of Patents With Issuance Of Istaroxime Patent For Japan
Portfolio Pulse from Benzinga Newsdesk
Windtree Therapeutics has announced the issuance of a new patent for its investigational therapy, istaroxime, in Japan. This patent covers the intravenous administration of istaroxime for treating acute heart failure, with a focus on improving heart function and safety. The patent is valid until 2039.
October 17, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Windtree Therapeutics has received a new patent in Japan for its heart failure treatment, istaroxime. This strengthens its intellectual property portfolio and could enhance its market position in Japan.
The issuance of a new patent in Japan for istaroxime is a positive development for Windtree Therapeutics. It strengthens the company's intellectual property and could lead to increased market opportunities in Japan, potentially boosting investor confidence and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100